Proteinuria as a predictor of risk of cardiovascular disease: A new insight;Białkomocz jako wskaźnik ryzyka powikłań sercowo-naczyniowych - Nowe dane

Polskie Archiwum Medycyny Wewnetrznej

Volumn 117, Issue 9, 2007, Pages 411-414

  Sulikowska, Beata ^a   Manitius, Jacek ^a,b  

^a Nadcisnienia Tetniczego I Chorob Wewnetrznych   (Poland)

^b Katedra I Klinika Nefrologii Nadcisnienia Tetniczego I Chorob Wewnetrznych   (Poland)

Author keywords

Albuminuria; Proteinuria; Risk of cardio vascular disease; Uric acid

Indexed keywords

ALBUMIN;

ALBUMINURIA; CARDIOVASCULAR DISEASE; DISEASE COURSE; HUMAN; MICROALBUMINURIA; MORBIDITY; MORTALITY; PROTEINURIA; REVIEW; URINE;

EID: 36549081882     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.202     Document Type: Review

References (37)

1. Brand RJ, Rosenman RH, Sholtz RI, et al. Multivariate prediction of coronary heart disease in the Western Collaborative Group Study compared to findings of the Framingham Study. Circulation. 1976; 53: 348-355.
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and risk of death, cardiovascular events and hospitalization. N Engl J Med. 2004; 351: 1296-1305.
3. Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002; 13: 745-753.
4. Postȩpowanie w przewlekłej chorobie nerek. Med Prakt. Wyd specj. 2004; 7: 8.
5. Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Horn Study. Kidney Int. 2002; 62: 1402-1407.
6. Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol. 2002; 57: 327-335.
7. Verhaven JC, Hillege HL, Burgerhof JGM, et al. The association between atherosclerotic risk factors and renal function in general population. Kidney Int. 2005; 67: 1967-1973.
8. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease. Am J Kidney Dis. 2000; 35 (Suppl 1): S117-S131.
9. Feldman HL, Appel LJ, Chertow GM, et al. The Chronic Renal Insufficiency Cohort (CRIC). J Am Soc Nephrol. 2003; 14: S148-S153.
10. Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002; 39 (Suppl 1): S1-S266.
11. Hebert LA, Wilmer WA, Falkenhain ME, et al. Renoprotection: one or many therapies. Kidney Int. 2001; 59: 1211-1226.
12. de Zeeuw D, Remuzzi G, Parving H-H, Keane WF. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004; 110:921.
13. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systemic overview of the literature. Arch Intern Med. 1997; 157: 1413-1418.
14. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects: Islington Diabetes Survey. Lancet. 1988; 2: 530-533.
15. Hillege HL, Fidler V, Diercks GF, Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106: 1777-1782.
16. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension and diabetes. Circulation. 2004; 110:32-35.
17. Redon J. Microalbuminuria and risk in hypertension. Hypertension. 2005; 46:19-20.
18. Dimmitt SB, Lindquist TL, Mamotte CD, et al. Urine albumin excretion in healthy subjects. J Human Hypert. 1993; 7: 239-243.
19. Campese VM, Bianchi S, Bigazzi R. Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int. 1999; 56 (Suppl): S10-S13.
20. Asselbergs FW, Diercks GF, Hillege HL, Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004; 110: 2809-2816.
21. Deckert T, Feld-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989; 32: 219-226.
22. Clausen P, Jensen JS, Jensen G, et al. Endothelial haemostatic factors are associated with progression of urinary albumin excretion in clinically healthy subjects: a 4-year prospective study. Clin Sci. 1999; 97: 37-43.
23. Stehouwer CD, Fischer HR, van Kuijk AW, et al. Endothelial dysfunction precedes the development of microalbuminuria in insulin-dependent diabetes mellitus. Diabetes. 1995; 44: 561-564.
24. Brunner H, Cockroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and disease. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005; 23: 233-246.
25. Stehouwer CD, Gall MA, Twisk JW, et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Progressive, interrelated, and independently associated with risk of death. Diabetes. 2002; 51: 1157-1165.
26. Pannacciulli N, Cantatore FP, Minenna A, et al. Urinary albumin excretion is independently associated with C-reactive protein levels in overweight and obese non-diabetic premenopausal women. J Intern Med. 2001; 250: 502-507.
27. Tsioufis C, Dimitriadis K, Antoniadis D, et al. Inter-relationships of microalbuminuria with other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Am J Hypertens. 2004; 17: 470-476.
28. Pedrinelli R, Giampierto O, Carmassi F et al. Microalbuminuria and endothelial dysfunction in essentials hypertension. Lancet. 1994; 344: 14-18.
29. Choi HS, Sung KC. The prevalence and risk factors of microalbuminuria in normoglycemic normotensive adults. Clin Nephrol. 2006; 65: 256-261.
30. Butler R, Morens AD, Belch JJ, et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000; 35: 746-751.
31. Pellicano R, Kerr PG,Atkins RC. What have learned from clinical trials on prevention? Kidney Int. 2005; 67 (Suppl 94): S101-S106.
32. Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int. 1999; 56: 1879-1885.
33. Dang A, Zhang Y, Liu G, et al. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population. J Hum Hypertens. 2006; 20: 45-50.
34. Bianchi S, Bigazzi R, Campese VW. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis. 1999; 34: 973-995.
35. Palatini P, Mormino P, Mos L, HARVEST Study Group, et al. Microalbuminuria, renal function and development of sustained hypertension: a longitudinal study in the early stage of hypertension. J Hypertens. 2005; 23: 175-182.
36. Cerasola S, Cottone S, Mule G, et al. Microalbuminuria, renal dysfunction and cardiovascular complications in essential hypertension. J Hypertens. 1966; 14: 915-920.
37. Cohn JN. Arteries, myocardium, blood pressure and cardiovascular risk: towards a revisited definition of hypertension. J Hypertens. 1998; 16: 2117-2124.